Topo Ⅱ在脑原发性胶质瘤中表达的临床意义(附101例分析)  

Study of the clinical significance of DNA topoisomerase I expressed in primary glioma

作　　者：梅文忠[1] 何理盛[1] 林震涛[1] 

机构地区：[1]福建医科大学附属第一医院神经外科,350005

出　　处：《福建医药杂志》2004年第2期89-90,共2页Fujian Medical Journal

摘　　要：目的 探讨DNA拓扑异构酶Ⅱ(TopoⅡ)在脑原发性胶质瘤中的表达及其临床意义,以进一步深入研究原发性脑胶质瘤多药耐药(MDR)的机制。方法 利用免疫组化技术S-P法检测原发性脑胶质瘤及正常脑组织中TopoⅡ的表达。结果 TopoⅡ在正常脑组织中没有表达;原发性胶质瘤中TopoⅡ的表达率为59.4％(60/101),阳性表达位于肿瘤细胞核,TopoⅡ在原发性胶质瘤中的表达强度与病理分级呈负相关。结论TopoⅡ在原发性胶质瘤中的不同表达与胶质瘤MDR的产生密切相关,检测胶质瘤细胞TopoⅡ的表达可预示不同的化疗敏感性及肿瘤恶性度,有利于指导临床更加合理地选择化疗方案及进行个体化化疗。Objective To analyze the expression of Topo Ⅱ in primary glioma and normal brain tissues in order to explore the clinical significance and to study deeply the mechanism of multidrug resistance (MDR) in glioma. Methods 101 cases of paraffin-embedded primary glioma tissue sections and 25 cases of paraffin-embedded normal brain tissue sections were analyzed for the presence of Topo Ⅱ by means of immunohistochemistry. Results There were no expression of Topo Ⅱ in normal brain tissues. The expression of Topo Ⅱ in primary glioma was 59. 4% (60/101), and the positive staining located in tumour cell nuclie. Conclusion Our research suggests that the patients with high level of Topo Ⅱ are the best indication of chemotherapy. Electing different drug according to different mechanism should be the key to improve the efficiency of chemotherapy.

关 键 词：TopoⅡ 脑原发性胶质瘤 表达 免疫组化 

分 类 号：R739.4[医药卫生—肿瘤]